← Banking With Billy News

Camp4 Therapeutics has secured Australian regulatory and ethics approval for a Phase 1/2 trial of its lead SYNGAP1 candidate, the first potential disease-modify

BWB News TV • 2026-07-27 11:11 UTC • By Billy Odell Tucker-Robinson
Camp4 Therapeutics has secured Australian regulatory and ethics approval for a Phase 1/2 trial of its lead SYNGAP1 candidate, the first potential disease-modify
Camp4 Therapeutics has secured Australian regulatory and ethics approval for a Phase 1/2 trial of its lead SYNGAP1 candidate, the first potential disease-modifying therapy for the disorder. Patient recruitment is set to begin soon.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly